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The dynamic interaction between cancer cells and immune cells is a critical concern for developing effective
tumor immunotherapies. In a recent issue of Nature Cell Biology, Zhou et al. (2015) report that glioma stem
cells secrete Periostin (POSTN), which recruits tumor-associated macrophages (TAMs) and supports the tu-
mor-promoting M2 subtype.The development of more effective tumor
immunotherapy requires a better under-
standing of the interplay between tumor
cells and immune cells in the tumormicro-
environment. Tumor-infiltrating immune
cells play important roles in regulating tu-
mor progression with potential values in
diagnostic determination and therapeutic
intervention. Tumor-induced polarization
is one of the special features of immune
cells that reside in solid tumors, which
are defined by attenuated immune sur-
veillance functions and enhanced pro-
tumor activities. Through this modulation,
tumor cells may avoid the immune surveil-
lance of host immune system and influ-
ence the tumor microenvironment in favor
of their malignant progression. On the
other hand, immune cells including mac-
rophages and T and B cells, as well as
dendritic cells, may attempt to counteract
the development of tumors. These dispa-
rate effects emphasize the complexity of
the tumor immune-environment and the
multi-dimensional interactions between
tumor cells and immune cells.
Tumor-infiltrating leukocytes, which
are constantly detected in bulk tumors,
are often orchestrated by the tumor
microenvironment to display a tumor-
supportive phenotype. This ‘‘polarization’’
has been described for several myeloid
cells, particularly macrophages (Bruno
et al., 2014). In glioblastoma (GBM), infil-
tration and enrichment of tumor-associ-
ated macrophages (TAMs) is a common
feature. Furthermore, TAMs in GBMs are
abundantly located in the perivascular
niches, where glioma stem cells (GSCs)
are also enriched (Ye et al., 2012; Pietras
et al., 2014), suggesting a putative corre-
lation between GSCs and TAMs. A recentstudy by Bao’s group identified Periostin
(POSTN) as one of the key cytokines pref-
erentially secreted by GSCs (Zhou et al.,
2015). The authors also observed a posi-
tive correlation between POSTN protein
levels and TAM density in human GBM
specimens, suggesting that POSTNmight
potentially enable TAM recruitment by
GSCs. Zhou et al. validated this hypothe-
sis by using an intracranial GBM tumor
model with implantation of human GSCs
in mouse brains. The results showed
that silencing of POSTN caused a re-
markable reduction of TAM density, a sig-
nificant inhibition of tumor growth, and
extended survival of mice bearing GSC-
derived tumors.
It has been shown that TAMs are main-
tained as at least two functional subtypes
(M1 and M2) in tumors. The M2 subtype
displays a pro-tumor effect (Condeelis
and Pollard, 2006), while the M1 subtype
mainly functions in tumor suppression
(Qian and Pollard, 2010). To investigate
which subtype of TAM is recruited or
maintained by POSTN in GBM tumors,
Zhou et al. used distinctive biomarkers
for theM1 subtype (MHCII and CD11 pos-
itive) and the M2 subtype (Fizz-1, CD163,
and Arg1 positive) to distinguish TAMs in
GSC-derived tumors (Zhou et al., 2015).
They demonstrated that disruption of
POSTN markedly reduced the number of
M2-TAMs while increasing the number
of M1 TAMs in the GSC-derived tumors.
Using mouse intraperitoneal macro-
phages and U937-derived macrophage-
like cells, they found an induction of M2
macrophage features by POSTN treat-
ment. Consistently, POSTN co-distrib-
uted with M2 subtype macrophages and
its protein level correlated with M2 sub-Cell Stem Celltype macrophage density in human
GBM specimens. Thus, POSTN not only
recruits TAMs but also maintains the M2
subtype of TAMs in GBMs. However,
further investigation is required to address
whether GSC-secreted POSTN directly
triggers the differentiation of monocytes
into M2 TAMs or if it regulates the switch
of TAMs from the M1 to M2 subtype.
The origin of the TAMs in GBMs was
another disputed issue that was clarified
by Zhou et al. By using specific markers
for microglia (CX3CR1) and monocyte-
derived macrophages (CCR2), Zhou
et al. demonstrated that the TAMs in
GBM xenografts as well as primary
human GBM specimens were mainly
monocyte-derived macrophages from
peripheral blood (Zhou et al., 2015). The
finding that GBM TAMs derive from
circulating monocytes may be therapeu-
tically relevant because the tumor hom-
ing feature of circulating monocytes
could potentially provide an endogenous
vector for the development of anti-tumor
drugs. This strategy would employ cells
that are easy to isolate from patients
and could traverse the blood-brain bar-
rier (BBB), which can limit the efficiency
of anti-GBM drugs. Importantly, the pe-
ripheral blood monocytes could also be
potentially manipulated to reactivate their
phagocytic function and their effects
may synergize with those of other im-
mune cells (e.g., Th2 and Tregs) to kill
tumor cells in an anti-inflammatory tumor
milieu.
The identification of crucial factors
bridging cancer stem cells (CSCs) and
their niches could provide potential
implications for CSC targeting in tumor
therapy. The role of POSTN as a potent16, March 5, 2015 ª2015 Elsevier Inc. 219
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Figure 1. Glioma Stem Cells Recruit Monocyte-Derived Tumor-Associated Macrophages to
Promote Glioblastoma Tumor Growth
(A) Glioma stem cells (GSCs) in perivascular niches secrete Periostin (POSTN) to attract circulating mono-
cytes.
(B) The emigration and differentiation of recruited monocytes in GSC niches.
(C) POSTN maintains M2 tumor-associated macrophages (TAMs) that promote tumor growth.




phages in CSC niches may be only one
aspect of the importance of POSTN in
tumorigenesis. A recent report pointed
out that POSTN also supports homing of
breast CSCs during metastatic coloniza-
tion (Malanchi et al., 2012). In addition to
regulating the tumor microenvironment,
POSTN has been shown to promote pro-
liferation, migration, and invasion of tumor
cells in other malignant cancers (Bao
et al., 2004). The findings by Zhou et al.
(2015), together with previous studies,
reinforce the importance of POSTN as
an essential factor in CSC niches and a
critical tumor-promoting cytokine with
cell-intrinsic functions and suggest that
strategies aimed at blocking POSTN220 Cell Stem Cell 16, March 5, 2015 ª2015signaling may provide an effective anti-tu-
mor therapy by simultaneously targeting
CSCs and the tumor microenvironment
(Figure 1).
The traditional radiation and chemo-
therapy treatments focusing on ‘‘elimina-
tion’’ of tumor cells have limitations in
improving survival of individuals with
GBM. The recent progress made in can-
cer immunotherapy, which harnesses
the immune system to battle tumors,
provides an attractive approach to im-
prove cancer treatment. The success of
immunotherapeutic antibodies directed
against cytotoxic T lymphocyte antigen-
4 (CTLA-4) and programmed death-1
(PD-1) has proved the potential of cancer
immunotherapy in melanoma and otherElsevier Inc.tumor types (Couzin-Frankel, 2013).
TAMs have a high infiltration rate into tu-
mors including GBMs and their presence
strongly correlates with tumor malig-
nancy. Targeting TAMs instead of tumor
cells has had clear clinical outcomes in
fibrosarcoma and ovarian and lung can-
cers (Germano et al., 2013). The findings
by Zhou et al. (2015) on POSTN-recruited
TAMs provide us a new clue for
designing anti-TAM-based treatments.
Future strategies aimed at targeting
POSTN-mediated TAM recruitment may
prove synergistic with more traditional
GBM treatment methods such as surgi-
cal resection and chemotherapy. In
conclusion, the study by Zhou et al.
(2015) greatly enhances our understand-
ing of the role of TAMs in tumor niches
and their interaction with tumor cells.
These findings may help enlarge the
scope of cancer immunotherapy and
facilitate the development of GSC-target-
ing treatments to improve the survival of
GBM patients.REFERENCES
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